hexamethonium has been researched along with Agranulocytosis in 1 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| LOUWERENS, B | 1 |
| SMELIK, PG | 1 |
1 other study available for hexamethonium and Agranulocytosis
| Article | Year |
|---|---|
The effect of hexamethonium chloride on the eosinopenic response during stress in rats.
Topics: Agranulocytosis; Animals; Cardiovascular Agents; Eosinophils; Hexamethonium; Leukocyte Count; Mental | 1953 |